Hanmi Pharm. Co., Ltd. (KRX:128940)

Market Cap	4.99T
Revenue (ttm)	1.47T
Net Income (ttm)	107.35B
Shares Out	12.68M
EPS (ttm)	8,465.57
PE Ratio	46.48
Forward PE	29.76
Dividend	1,250.00 (0.31%)
Ex-Dividend Date	n/a

Volume	183,461
Average Volume	154,872
Open	409,000
Previous Close	405,500
Day's Range	390,500 - 409,500
52-Week Range	214,500 - 439,500
Beta	0.67
RSI	65.24
Earnings Date	Oct 29, 2025

About Hanmi Pharm.

Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company’s products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). The company ha...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1973
• Employees: 2,343
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 128940

Financial Performance

In 2024, Hanmi Pharm.'s revenue was 1.50 trillion, an increase of 0.31% compared to the previous year's 1.49 trillion. Earnings were 121.32 billion, a decrease of -17.04%.